285 related articles for article (PubMed ID: 34197267)
1. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Cicero AFG; Fogacci F; Cincione I
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
3. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
Nguyen H; Akamnonu I; Yang T
Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
5. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
Lekuona I; Pintó X
Clin Investig Arterioscler; 2021 May; 33 Suppl 1():58-64. PubMed ID: 33966815
[TBL] [Abstract][Full Text] [Related]
7. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
8. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
9. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
Masana Marín L; Plana Gil N
Clin Investig Arterioscler; 2021 May; 33 Suppl 1():53-57. PubMed ID: 33966814
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
12. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
13. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
16. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
[TBL] [Abstract][Full Text] [Related]
17. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
[TBL] [Abstract][Full Text] [Related]
18. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
19. Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Bhagavathula AS; Al Matrooshi NO; Clark CCT; Rahmani J
Clin Drug Investig; 2021 Jan; 41(1):19-28. PubMed ID: 33368025
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
